Evidence map›Paper›PMID 40736684›Full record

ArticleLung2025

Stratifying GAP Stages by MUC5B rs35705950 T-Allele Carriage Refines Survival Prediction in IPF.

Joanne J van der Vis, Antje Prasse, Elisabetta A Renzoni, Carmel J W Stock, Toby M Maher, Francesco Bonella, Raphael Borie, Bruno Crestani, Wim A Wuyts, Philip L Molyneaux and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joanne J van der VisILD Center of Excellence, Member of European Reference Network-Lung, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. a.vandervis@antoniusziekenhuis.nl.ORCID https://orcid.org/0000-0002-6727-8416
Antje PrasseDivision of Pulmonology, Hannover Medical School & DZL BREATH, Hannover, Germany.
Elisabetta A RenzoniInterstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Carmel J W StockInterstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Toby M MaherNational Heart and Lung Institute, Imperial College London, London, UK.
Francesco BonellaCenter for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.
Raphael BorieInserm, U1152, Laboratoire d'excellence, INFLAMEX, 75018, Paris, France.
Bruno CrestaniInserm, U1152, Laboratoire d'excellence, INFLAMEX, 75018, Paris, France.
Wim A WuytsUnit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Philip L MolyneauxInterstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Johannes C KelderDepartment of Epidemiology and Statistics, St Antonius Hospital, Nieuwegein, The Netherlands.
Jan C GruttersILD Center of Excellence, Member of European Reference Network-Lung, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Coline H M van MoorselILD Center of Excellence, Member of European Reference Network-Lung, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.

Funding

ZonMw 10070012010004
6 · The paper itself

Abstract

The genetic contribution to idiopathic pulmonary fibrosis (IPF) has become increasingly evident, enabling its translation into clinical practice. MUC5B rs35705950 has emerged as a promising prognostic biomarker. The gender-age-physiology (GAP)-model is regularly used for IPF survival prediction. In this retrospective real-world study, GAP-stages were stratified by MUC5B T-allele carriage. European patients with IPF were included in a discovery (n = 663), and replication (n = 738) cohort. The GAP+MUC5B-model was significantly more accurate compared to the GAP-model (all cohorts p < 0.001), with a modest improvement in discrimination (ΔC = 0.023; C = 0.685, 95%CI 0.665-0.704). Within each GAP-stage, T-allele carriers had significantly better median transplant-free survival outcomes than non-carriers (p < 0.001): In the combined cohort (n = 1401) survival for GAP-stage I T carriers was 70 months (m) vs 48m for T non-carriers; stage II T vs non-T: 41 vs 31m; stage III T vs non-T: 23 vs 12m. Addition of MUC5B rs35705950 T-carriership enhances GAP-based prognostication and aids clinical decision-making.

Indexed as

Idiopathic Pulmonary FibrosisMucin-5BAgedAllelesFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesMUC5B protein, humanMucin-5BGAP-modelIPFMortalityMUC5BPrognosisSurvival

Identifiers

PMID40736684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.